pharmaphorum
MARCH 15, 2022
Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer’s therapy Aduhelm, handing over full responsibility to its US counterpart. The changes to the terms of their longstanding collaboration on Aduhelm (aducanumab) means that Eisai’s profit-share converts to a simple royalty rate on revenues from 1 January next year.
Outsourcing Pharma
MARCH 15, 2022
The US- and Hungary-based pharma firms will work on research, development, and commercialization of dopamine receptor modulators for potential treatments.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 15, 2022
A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to develop standardised, digital clinical measures that can be used in the development of therapies for Alzheimer’s disease and related dementias. According to the consortium – which includes drugmakers Biogen, Eisai, Eli Lilly and Merck & Co – there is a lack of measures that can be used to determine whether new therapies for Alzheimer’s are actually working.
Pharma Times
MARCH 15, 2022
COVID-19 has highlighted another significant widespread problem – the mental health pandemic
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MARCH 15, 2022
The new normal is already here. Get used to it. The COVID-19 pandemic has radically disrupted traditional medical society conferences in a way that could scarcely have been imagined in 2019. The vast majority of societies were able to transition their planned physical events to virtual formats within remarkably short periods of time, and some delivered impressive attendee experiences.
Pharma Times
MARCH 15, 2022
The initiative will catalyse discovery and early development of antiviral medicines for future pandemics
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
MARCH 15, 2022
Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development. Blackstone will provide €300 million in funding for the project, which will focus on a subcutaneous formulation of Sarclisa (carfilzomib) that is due to start a pivotal study later this year.
pharmaphorum
MARCH 15, 2022
The latest version of Abbott’s FreeStyle Libre continuous glucose monitor is now available via the NHS to eligible people with diabetes in the UK. Abbott’s wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user’s smartphone for up to 14 days, allowing them to adjust treatment as needed.
pharmaphorum
MARCH 15, 2022
In a fireside chat hosted by pharmaphorum’s Jonah Comstock, Healthware Group CEO Roberto Ascione (author of the recent book “The Future of Health”) and Politecnico di Milano Professor Emanuele Lettieri will discuss recent trends in digital transformation in healthcare and life sciences that prompted the creation of the Programme as well as share a little about the programme itself.
pharmaphorum
MARCH 15, 2022
There are approximately 300 million people around the world living with a rare disease. Yet, until relatively recently, there was limited focus on this heterogenous population. By their nature, rare diseases are just that – rare – with a wide array of symptoms and severities affecting patients, which makes it challenging for pharma companies to identify opportunities to develop effective new treatments.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
MARCH 15, 2022
Gene sequencing specialist Illumina has started rolling out a new test that looks for a battery of tumour-associated genes from a single tissue sample, and could be used to help guide treatment for a broad range of cancers. The TruSight Oncology in vitro diagnostic (IVD) test is being launched first in Europe and according to Illumina’s cancer head Kevin Keegan can match patients with suitable therapies “according to clinical guidelines or clinical trials, based on their tumour profi
Expert insights. Personalized for you.
118 
Let's personalize your content